Certain Patents Sample Clauses

The 'Certain Patents' clause defines which specific patents are covered or affected by the agreement. It typically lists or references particular patent numbers, patent applications, or patent families that are included, and may clarify whether future patents or related continuations are also encompassed. This clause ensures that both parties have a clear understanding of the scope of intellectual property rights involved, thereby preventing disputes over which patents are subject to the agreement's terms.
Certain Patents. Immediately following the Closing, Purchaser shall grant to Pfizer or its designated Affiliate a non-exclusive, perpetual, royalty-free, worldwide license to use the Patents set forth as item 2 on Schedule 2.1(a)(i), it being understood that Pfizer or such Affiliate shall not use such Patents in connection with any oral contraceptive products.
Certain Patents. 33 ARTICLE VIII INDEMNIFICATION............................................................. 33
Certain Patents. If Sellers obtain a license that (i) is reasonably satisfactory to Purchasers and (ii) grants to Purchasers and their Affiliates a royalty-free, fully paid right and license to use, in connection with the Business as operated by Purchasers after the Closing, all patents and patent applications (1) the subject matter of which have been used or held for use in connection with the Business by Sellers and (2) that have been issued or filed in the name of ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ and that the Lemelson Medical, Education & Research Foundation Limited Partnership or any other Person claims an ownership interest in, Purchasers shall pay to U.S. Seller $175,000, PROVIDED, that such license is granted and in effect prior to the earlier of (x) the date that is six months after the Closing Date and (y) the date that is 20 days after the date that U.S. Purchaser notifies U.S. Seller that (A) a Person claiming an ownership interest in any such patents or patent applications has contacted a Purchaser or any of its Affiliates concerning the licensing or use by a Purchaser or any of its Affiliates of any such patents or patent applications in which such Person claims an ownership interest and (B) such Purchaser or one of its Affiliates has decided to commence negotiations with such Person regarding such matter. After the earlier to occur of (x) and (y) in the immediately preceding sentence, if a Purchaser or any of its Affiliates shall (i) obtain a license to use any such patents or patent applications in connection with the Business as operated by Purchasers after the Closing or (ii) incur any Loss relating to or arising out of or in connection with the use of any such patents or patent applications by a Purchaser or any of its Affiliates in connection with the Business as operated by Purchasers after Closing, Sellers shall, upon notice from a Purchaser, pay to such Purchaser 80% of the cost to obtain such license or such Loss, up to a maximum amount of $400,000 payable by Sellers.
Certain Patents. 28 SECTION 7.8 Payment...........................................................................29
Certain Patents. If ▇▇▇▇▇▇-▇▇▇▇, in its sole discretion, decides that it no longer desires to prosecute or maintain any patent or application within the Research Patents or the Patents and Applications, ▇▇▇▇▇▇-▇▇▇▇ shall so notify ▇▇▇▇▇▇▇▇▇▇▇. ▇▇▇▇▇▇▇▇▇▇▇ shall then have the right to assume prosecution and maintenance of such specific patent or application. ▇▇▇▇▇▇-▇▇▇▇ shall, upon ▇▇▇▇▇▇▇▇▇▇▇'▇ request, take all actions and execute all documents and instruments reasonably necessary to transfer such right to prosecute and maintain, on ▇▇▇▇▇▇-▇▇▇▇'▇ behalf, such specific patents and applications to ▇▇▇▇▇▇▇▇▇▇▇. For any such patent application for which ▇▇▇▇▇▇▇▇▇▇▇ has undertaken under this subsection (b) to continue prosecution efforts, ▇▇▇▇▇▇▇▇▇▇▇ shall provide to ▇▇▇▇▇▇-▇▇▇▇ copies of all documents, correspondence and materials reasonably relating to the prosecution by ▇▇▇▇▇▇▇▇▇▇▇ of such patent applications in sufficient time to allow ▇▇▇▇▇▇-▇▇▇▇ to review such materials and comment thereon. ▇▇▇▇▇▇▇▇▇▇▇ shall reasonably consider and accommodate any recommendations provided by ▇▇▇▇▇▇-▇▇▇▇ regarding patent filing and/or prosecution of such patent applications. In addition, if ▇▇▇▇▇▇-▇▇▇▇ has a reasonable justification for any changes to such prosecution based on ▇▇▇▇▇▇-▇▇▇▇'▇ own patent prosecution and enforcement strategy, then ▇▇▇▇▇▇▇▇▇▇▇ will modify or change any such prosecution efforts as requested by ▇▇▇▇▇▇-▇▇▇▇, including without limitation deleting or amending particular claims in such applications and/or modifying any arguments made in communications with relevant patent authorities. For clarity, it is understood and agreed that the foregoing right in this subsection (b) of ▇▇▇▇▇▇▇▇▇▇▇ to undertake to continue the prosecution and maintenance, on ▇▇▇▇▇▇-▇▇▇▇'▇ behalf, of specific patents and patent applications does not affect the licenses granted to ▇▇▇▇▇▇-▇▇▇▇ under this Agreement.
Certain Patents. The Company and others are parties to the action (the "Patent-Related Litigation") to be identified as item 1 in Section 7.7 of the Disclosure Statement relating to that certain United States Patent identified therein (the "Subject Patents"). Notwithstanding anything herein to the contrary, the following provisions shall be applicable with respect to the Patent-Related Litigation from and after the Closing Date: (a) Without limiting in any way the retention by the Company of all of its liabilities, the Buyer and the Company shall assume full responsibility for and control of the Patent-Related Litigation and all liability arising from or relating to the Subject Patents in dispute in the Patent-Related Litigation. (b) The aggregate Patent Damages (as hereinafter defined) shall be borne by the parties hereto in the following proportions: the Company - 50%; and Seller - 50%; provided that the amounts to be borne by Seller shall only be paid (if at all) to the extent that the contingent consideration payable to Seller pursuant to Section 1.3 hereof is required to be paid pursuant to such section, and such amounts to be paid by Seller shall be paid by reducing the amounts otherwise payable under Sections 1.3(a) and 1.3(b) hereof. Notwithstanding anything to the contrary herein, the Company shall not be responsible for any fees or expenses of any counsel to Seller (or any of its Affiliates) in connection with the Patent-Related Litigation. (c) For purposes hereof, "Patent Damages" shall mean any and all of the following amounts paid or payable by or on behalf of the Company that arise from or relate to the Subject Patents, including, without limitation, the Patent-Related Litigation, (including, without limitation, any amounts capable of reasonable estimation in connection with any pending or threatened matter relating to the Subject Patents): (i) reasonable attorneys' fees incurred in defending any claim or prosecuting any defense or counterclaim asserted in the Patent-Related Litigation, including, without limitation, any and all appeals; and (ii) all losses, liabilities, damages, demands, claims, suits, actions, judgments, causes of action, assessments, costs and expenses, including, without limitation, interest, penalties, royalties, license fees, any and all reasonable expenses incurred in investigating, preparing or defending the Patent-Related Litigation and amounts paid in settlement thereof.
Certain Patents. 107- ARTICLE XV GUARANTIES . . . . . . . . . . . . . . . . . . . . . . . . -107- 15.1 GUARANTY OF SELLERS' PARENT . . . . . . . . . . . . . -107- 15.2 GUARANTY OF PURCHASERS' PARENT . . . . . . . . . . . -108- EXHIBITS Exhibit A-1 Form of Assignment and Assumption Agreement (U.S.) Exhibit A-2 Form of Assignment and Assumption Agreement (Canada) Exhibit B Information Services Support Principles Exhibit C-1 Form of Shared Facilities Agreement (U.S.) Exhibit C-2 Form of Shared Facilities Agreement (Canada) Exhibit D Form of Temporary Trademark Agreement Exhibit E-1 Form of Transition Services Agreement (U.S.) Exhibit E-2 Form of Transition Services Agreement (Canada) Exhibit E-3 Form of Warehouse Services Agreement Exhibit F-1 Form of ▇▇▇▇ of Sale (U.S.) Exhibit F-2 Form of ▇▇▇▇ of Sale (Canada) Exhibit G-1 Form of Opinion of Counsel for U.S. Seller Exhibit G-2 Form of Opinion of Counsel for Canadian Seller Exhibit H-1 Form of Opinion of Counsel for U.S. Purchaser Exhibit H-2 Form of Opinion of Counsel for Canadian Purchaser Exhibit 3.2(a) Example of Net Working Capital Calculation -v- ASSET PURCHASE AGREEMENT ------------------------ THIS ASSET PURCHASE AGREEMENT is made as of the 22nd day of February, 1999, by and among ORC ACQUISITION CORP., a Delaware corporation ("U.S. PURCHASER"), 3026186 Nova Scotia Company, a Nova Scotia company ("CANADIAN PURCHASER")(each of U.S. Purchaser and Canadian Purchaser a "PURCHASER" and collectively, the "PURCHASERS"), Ameritech Corporation, a Delaware corporation ("PURCHASERS' PARENT"), Anixter Inc., a Delaware corporation ("U.S. SELLER"), Anixter Canada Inc., a Canadian corporation ("CANADIAN SELLER") (each of U.S. Seller and Canadian Seller a "SELLER" and collectively, the "SELLERS"), and Anixter International Inc., a Delaware corporation ("SELLERS' PARENT"). Certain capitalized terms used herein are defined in Article I.

Related to Certain Patents

  • Patents and Patent Applications To the Company’s knowledge, all patents and patent applications owned by or licensed to the Company or under which the Company has rights have been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such applications have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which could reasonably be expected to preclude the grant of a patent in connection with any such application or could reasonably be expected to form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.

  • Prosecution of Patents (a) The Licensor shall be solely responsible for preparing, prosecuting and maintaining the BENTLEY Patents. (b) Each Party shall cooperate with the other Party to execute all required papers and instruments and to make all required oaths and declarations as may be necessary in the preparation and prosecution of all such patents and other applications and protections referred to in this Section 9.1.

  • Enforcement of Patent Rights 2.10.1 If either party hereto learns at any time of any infringement or threatened infringement by any other person of any enforceable Patent Rights owned by or licensed to the other party after the Effective Date, that party shall give notice of that infringement or threatened infringement to the other party. The parties shall then consult together as to the best course of action to pursue in response to such potential infringement, but neither party shall be obligated to institute legal action at its own expense. A good faith failure by one party to provide such notice to the other party shall not be deemed a breach of this Agreement and shall not give rise to a right of action by other party. 2.10.2 In the event that the parties do not reach an agreement as contemplated by Section 2.10.1 hereof as to the best course of action to pursue with respect to a potential infringement (i) Licensor shall have the right, but not the obligation, to institute legal action, through counsel of its own choosing and at its sole expense, to restrain any infringement or threatened infringement, or to recover damages therefor, of its enforceable Patent Rights, and (ii) Licensee shall have the right, but not the obligation, to institute legal action, through counsel of its own choosing and at its sole expense, to restrain any infringement or threatened infringement, or to recover damages therefor, of its enforceable Patent Rights in the Licensed Field. The party that bears the expenses of pursuing legal action against a third party infringer shall be entitled to any damages, lost profits or other monies recovered by judgment, decree, settlement, arbitration or otherwise, resulting from such legal action. 2.10.3 In the event that one party elects to institute legal action against a third party infringer, the other party shall fully cooperate in the prosecution of such action including joining as a party in suit when necessary to acquire standing to institute legal action pursuant to this Section 2.10; provided, however, that such other party shall be reimbursed for all reasonable out-of-pocket expenses incurred in providing such cooperation including its reasonable legal fees and expenses. The electing party shall reimburse the other party for all such expenses within thirty (30) days after its receipt of an invoice from the other party that describes such expenses in reasonable detail, with supporting documentation as appropriate.

  • Licensed Patents Immune Design, at its expense, shall have the first right to file, prosecute and maintain all Licensed Patents for which Immune Design has any exclusive rights under this Agreement using patent counsel reasonably approved by IDRI, including conducting any interferences, reexaminations, reissues, oppositions, or request for patent term extension relating thereto. Immune Design shall conduct such filing, prosecution and maintenance in good faith, taking into consideration IDRI’s retained rights hereunder, and consistent with reasonable business judgment, provide IDRI with all relevant or material documentation and proposed filing in the Territory so that IDRI may be concurrently and promptly informed of the continuing prosecution, and consult with IDRI with regards to Immune Design’s patent strategy with the Licensed Patents for which Immune Design has any exclusive rights under this Agreement. Licensed Patents in the name of IDRI shall remain in the name of IDRI. Immune Design shall use commercially reasonable efforts to ***, as applicable. To the extent such ***, Immune Design shall provide IDRI reasonable opportunity to review and comment on such prosecution efforts regarding such Licensed Patents in the Territory, and any IDRI comments will be reasonably considered in such prosecution efforts, and included to the extent affecting the IDRI Exclusive Field or IDRI Territory, as the case may be. If Immune Design determines in its sole discretion to abandon or not maintain any Licensed Patent for which Immune Design has any exclusive rights under this Agreement in the Territory, then Immune Design shall promptly provide IDRI with written notice of such determination at least sixty (60) days before any deadline for taking action to avoid abandonment and shall provide IDRI with the right, opportunity and reasonable assistance to prepare, file, prosecute and maintain such Licensed Patent in the applicable jurisdiction in IDRI’s sole discretion and at IDRI’s expense, provided that Immune Design shall provide such reasonable assistance at its own costs and expenses. If IDRI elects to prepare, file, prosecute and maintain such Licensed Patent in such jurisdiction for which Immune Design has any exclusive rights, then Immune Design’s license rights to such Licensed Patent in such country will become nonexclusive in such country under such Licensed Patent (and/or patent application). If IDRI desires Immune Design to file, in a particular jurisdiction, a Licensed Patent for which Immune Design has any exclusive rights under this Agreement that claims priority to another Licensed Patent for which Immune Design has any exclusive rights under this Agreement, IDRI shall provide written notice to Immune Design requesting that Immune Design file such patent application in such jurisdiction. If IDRI provides such written notice to Immune Design, Immune Design shall either (i) file and prosecute such patent application and maintain any patent issuing thereon in such jurisdiction and the Parties shall share the related costs and expenses (A) in countries *** on the basis of *** percent (***%) Immune Design: *** percent (***%) IDRI or (B) in countries within the IDRI Territory equally; or (ii) notify IDRI that Immune Design does not desire to file such patent application in such jurisdiction and provide IDRI with the opportunity to file and prosecute such patent application, provided that if IDRI files and prosecutes such patent application in such jurisdiction, then Immune Design’s license rights to such License Patent in such country will become nonexclusive in such country under such Licensed GLA Patent (and/or patent application). Immune Design shall be responsible for the costs and expenses incurred in connection with its own activities for filing, prosecuting and maintaining the Licensed Patents; IDRI shall be responsible for monitoring of such activities by IDRI.

  • Other Patents and Copyrights 15 5.7 Remedies ................................................... 16